Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients

@article{BlzquezPrez2013CostEffectivenessAO,
  title={Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients},
  author={Antonio Bl{\'a}zquez-P{\'e}rez and Ram{\'o}n San Miguel and Javier Mar},
  journal={PharmacoEconomics},
  year={2013},
  volume={31},
  pages={919-931}
}
Chronic hepatitis C is the leading cause of chronic liver disease, representing a significant burden in terms of morbidity, mortality and costs. A new scenario of therapy for hepatitis C virus (HCV) genotype 1 infection is being established with the approval of two effective HCV protease inhibitors (PIs) in combination with the standard of care (SOC), peginterferon and ribavirin. Our objective was to estimate the cost effectiveness of combination therapy with new PIs (boceprevir and telaprevir… CONTINUE READING